175 related articles for article (PubMed ID: 30588981)
1. Mammalian target of rapamycin inhibitors in a patient with polycystic kidney disease-1-tuberous sclerosis-2 contiguous gene syndrome.
Anandh U; Chandrasekar G; Agarwal V
Saudi J Kidney Dis Transpl; 2018; 29(6):1475-1479. PubMed ID: 30588981
[TBL] [Abstract][Full Text] [Related]
2. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
3. Imaging features of tuberous sclerosis complex with autosomal-dominant polycystic kidney disease: a contiguous gene syndrome.
Back SJ; Andronikou S; Kilborn T; Kaplan BS; Darge K
Pediatr Radiol; 2015 Mar; 45(3):386-95. PubMed ID: 25355409
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
5. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex.
Salussolia CL; Klonowska K; Kwiatkowski DJ; Sahin M
Annu Rev Genomics Hum Genet; 2019 Aug; 20():217-240. PubMed ID: 31018109
[TBL] [Abstract][Full Text] [Related]
6. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.
Somers MJ; Paul E
J Clin Pharmacol; 2015 Apr; 55(4):368-76. PubMed ID: 25402866
[TBL] [Abstract][Full Text] [Related]
7. Possible prevention of tuberous sclerosis complex lesions.
Kotulska K; Borkowska J; Jozwiak S
Pediatrics; 2013 Jul; 132(1):e239-42. PubMed ID: 23733802
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
Franz DN; Krueger DA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
[TBL] [Abstract][Full Text] [Related]
9. Improvement in Renal Cystic Disease of Tuberous Sclerosis Complex After Treatment with Mammalian Target of Rapamycin Inhibitor.
Siroky BJ; Towbin AJ; Trout AT; Schäfer H; Thamann AR; Agricola KD; Tudor C; Capal J; Dixon BP; Krueger DA; Franz DN
J Pediatr; 2017 Aug; 187():318-322.e2. PubMed ID: 28600153
[TBL] [Abstract][Full Text] [Related]
10. Tubers from patients with tuberous sclerosis complex are characterized by changes in microtubule biology through ROCK2 signalling.
Ferrer I; Mohan P; Chen H; Castellsague J; Gómez-Baldó L; Carmona M; García N; Aguilar H; Jiang J; Skowron M; Nellist M; Ampuero I; Russi A; Lázaro C; Maxwell CA; Pujana MA
J Pathol; 2014 Jul; 233(3):247-57. PubMed ID: 24604753
[TBL] [Abstract][Full Text] [Related]
11. Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex-A Comprehensive Review of the Literature.
Jóźwiak S; Sadowski K; Kotulska K; Schwartz RA
Pediatr Neurol; 2016 Aug; 61():21-7. PubMed ID: 27222056
[TBL] [Abstract][Full Text] [Related]
12. Insight into response to mTOR inhibition when PKD1 and TSC2 are mutated.
Cabrera-López C; Bullich G; Martí T; Català V; Ballarín J; Bissler JJ; Harris PC; Ars E; Torra R
BMC Med Genet; 2015 Jun; 16():39. PubMed ID: 26077033
[TBL] [Abstract][Full Text] [Related]
13. Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.
Doğan V; Yeşil Ş; Kayalı Ş; Beken S; Özgür S; Ertuğrul İ; Bozkurt C; Örün UA; Karademir S
J Trop Pediatr; 2015 Feb; 61(1):74-7. PubMed ID: 25344617
[TBL] [Abstract][Full Text] [Related]
14. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
McEneaney LJ; Tee AR
Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
[TBL] [Abstract][Full Text] [Related]
15. TSC2/PKD1 contiguous gene syndrome, with emphasis on a case with an atypical mild polycystic kidney phenotype and a novel genetic variant.
Reyna-Fabián ME; Alcántara-Ortigoza MA; Hernández-Martínez NL; Berumen J; Jiménez-García R; Gómez-Garza G; González-Del Angel A
Nefrologia (Engl Ed); 2020; 40(1):91-98. PubMed ID: 31176519
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex.
Sato A; Kasai S; Kobayashi T; Takamatsu Y; Hino O; Ikeda K; Mizuguchi M
Nat Commun; 2012; 3():1292. PubMed ID: 23250422
[TBL] [Abstract][Full Text] [Related]
17. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
Henske EP; Rasooly R; Siroky B; Bissler J
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
[TBL] [Abstract][Full Text] [Related]
18. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.
Franz DN; Capal JK
Orphanet J Rare Dis; 2017 Mar; 12(1):51. PubMed ID: 28288694
[TBL] [Abstract][Full Text] [Related]
19. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
20. From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.
Ehninger D
Neuropharmacology; 2013 May; 68():97-105. PubMed ID: 22626986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
